KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Other Gross PP&E Adjustments (2016 - 2025)

Vertex Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 17 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $2.5 billion for Q4 2025, up 19.35% from a year ago — trailing twelve months through Dec 2025 was $2.5 billion (up 19.35% YoY), and the annual figure for FY2025 was $2.5 billion, up 19.35%.
  • Other Gross PP&E Adjustments for Q4 2025 was $2.5 billion at Vertex Pharmaceuticals, up from -$1.6 billion in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for VRTX hit a ceiling of $2.5 billion in Q4 2025 and a floor of -$1.6 billion in Q3 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$320.3 million (2021), compared with a mean of $11.4 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: increased 21.71% in 2021 and later crashed 349.63% in 2024.
  • Vertex Pharmaceuticals' Other Gross PP&E Adjustments stood at $1.5 billion in 2021, then rose by 13.4% to $1.7 billion in 2022, then increased by 13.89% to $1.9 billion in 2023, then increased by 7.21% to $2.1 billion in 2024, then rose by 19.35% to $2.5 billion in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $2.5 billion (Q4 2025), -$1.6 billion (Q3 2025), and -$1.3 billion (Q2 2025) per Business Quant data.